Drug discovery

#Artificial intelligence (AI) #Automation #Drug discovery #Webinar

Webinar: Gain a realistic view of what AI can do now for biotech R&D

AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data. In this webinar on… Read More

Webinar date:
Supported by Benchling
#News

CAR-T therapy for leukaemia
#ASH 2025 #Clinical trials #Drug discovery

CytoAgents announces positive preliminary data at ASH

Biotechnology company CytoAgents has presented preliminary safety data from its Phase Ib/IIa clinical trial of its lead drug candidate CTO1681. CTO1681 is an oral, small molecule immune modulator that uses a novel approach to prevent and mitigate both inflammation in the tumour microenvironment as well as toxicity frequently seen with… Read More

#News

Weight loss concept
#Clinical trials #Drug discovery #Obesity

Lilly begins obesity trial in the UK  

The first patient visit for Lilly’s five-year clinical trial assessing the company’s type-2 diabetes and weight-loss drug tirzepatide has taken place.  The SURMOUNT-REAL UK trial will last for five years and will assess the long-term effectiveness of tirzepatide on obesity outcomes when given in primary care settings. Taking place in Greater… Read More

#News

#Drug discovery

Ebook: Foundations of biospecimen success

Advances in biospecimen science are resolving long-standing challenges that have historically hindered research quality, reproducibility, and innovation across drug discovery, translational medicine, and biobanking. These gaps limit scientific progress because even the most sophisticated analytical tools depend on high-quality, well-characterised human biological specimens. This custom eBook for BioIVT explores the… Read More

#eBooks

Cell engineering
#DDW Turning Science into Business Symposium #Drug discovery #Events

Did you miss the DDW Symposium? Watch now on-demand

If you missed the DDW Turning Science into Business Symposium, you can now watch it on-demand here.  The event, which combined the latest drug discovery science and technology with market insight, took place at the Francis Crick Institute, London, UK on 4 November 2025. … Read More

#News

Automation and robotics
#Artificial intelligence (AI) #Automation #Drug discovery #Webinar

Webinar: How AI Agents transform day-to-day scientific work

AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data. In this webinar on… Read More

Webinar date:
Supported by Benchling
#News

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Webinar

Webinar: Leveraging untargeted metabolomics and lipidomics

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Webinar

The 2026 Biotech AI Report: Breakthroughs, bottlenecks, and the power shift shaping biotech’s AI future

This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More

Webinar date:
Supported by Benchling
#Webinars

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Webinar

Unbiased exploration of biological systems: Leveraging untargeted metabolomics and lipidomics for drug discovery

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar will begin with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#Webinars

Tower Bridge, London
#Drug discovery #Events #Investment #London Life Sciences Week #Market reporting

‘Good vibrations’ at London Life Science Week bode well for 2026

Jefferies’ Global Healthcare Conference held every November and coinciding with London Life Science Week (LLSW), is staking its claim as one of the world’s ‘must attend’ biotech investor events – and a vital barometer going into the New Year. DDW found the atmosphere refreshingly upbeat.  “Going into… Read More

#Exclusive Content #Trends & Analysis

#Awards #Drug discovery #Metabolomics

$30,000 award up for grabs in metabolomics research 

Biotechnology company NADMED has launched an award worth $30,000 to accelerate breakthroughs in metabolomics research.  The NADMED Award 2026 is a global initiative designed to empower scientific discovery in redox biology and accelerate innovation across medicine, life sciences, and biotechnology. The award aims to enable scientists and clinicians… Read More

#News

Cell therapy
#DDW Turning Science into Business Symposium #Drug discovery #Events

Watch DDW Symposium at Francis Crick Institute on-demand

If you missed the DDW Turning Science into Business Symposium, which took place at the Francis Crick Institute, London, UK on 4 November 2025, you can now watch it on-demand here.  This free half day event featured:  six in-depth presentations from industry experts… Read More

#News

#Artificial intelligence (AI) #Automation / robotics #Drug discovery

Standardising organoid workflows: How automation and AI enable reliable, scalable models – custom webinar with Galatek Nov 2025

Organoids have emerged as powerful in vitro models in disease modelling, drug screening, and regenerative medicine, but their complexity introduces major workflow challenges, from culture variability to labour-intensive handling. In this webinar, hosted by DDW and supported by Galatek, we will explore the evolving landscape of organoid research,… Read More

#Webinars

AI clinical trials concept
#Artificial intelligence (AI) #Automation #Drug discovery #Webinar

Webinar: Harness AI in ways that drive measurable R&D impact

AI has reached a turning point in biotech. Real-world scientific agents are beginning to automate the repetitive tasks that slow down research, and transform how we think about extracting insights from scientific data. In this webinar on… Read More

Webinar date:
Supported by Benchling
#News

Neuronal network
#Drug discovery #eBook #Neurodegenerative disorders #Neuroscience #Psychiatry

eBook: What’s new in neuroscience drug discovery?

The global neuroscience market has grown significantly in the last 10 years, driven predominantly by an ageing population and increasing cases of neurodegenerative diseases like Alzheimer’s disease (AD). The neuroscience market size was estimated at $44.65 billion in 2023 and is projected to reach $65.22 billion by 2030,… Read More

#News

DDW Neuroscience book cover
#Drug discovery #eBook #Neurodegenerative disorders #Neuroscience #Psychiatry

What’s new in neuroscience drug discovery?

This eBook, sponsored by Emulate, explores the latest developments in our understanding of neuroscience and the new therapies coming to market, spanning neurodegenerative diseases, genetic disorders, and psychiatry.

#DDW eBooks #Intelligence